Evidence map›Paper›PMID 39697424›Full record

ArticleWorld journal of oncology2024

Jie Luo, Kai Qin, Rong Quan He, Jian Di Li, Zhi Guang Huang, Bin Tong Yin, Tong Wu, Yu Zhen Chen, Di Yuan Qin, Jia Yuan Luo and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jie LuoDepartment of Oncology, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530007, Guangxi, China.
Kai QinDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530007, Guangxi, China.
Rong Quan HeDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Jian Di LiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Zhi Guang HuangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Bin Tong YinDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Tong WuDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Yu Zhen ChenDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Di Yuan QinDepartment of Computer Science and Technology, School of Computer and Electronic Information, Guangxi University, Nanning 530004, Guangxi, China.
Jia Yuan LuoDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Mei WuDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Bang Teng ChiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Gang ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Jian Jun LiDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530007, Guangxi, China.
Yu Bin HuangDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530007, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the present day, hepatocellular carcinoma (HCC) remains a formidable threat to human health. Actin-related protein 10 ( Methods: We conducted an integration of high-throughput datasets across various centers, analyzing Results: The standardized mean difference (SMD) of 0.34 (95% confidence interval (CI): 0.22 - 0.45, P < 0.05) and Conclusion: The upregulation of

Indexed as

Actin-related protein 10Hepatocellular carcinomaProspective therapeutic targetRisk factorTyrosine kinase inhibitor resistance

Identifiers

PMID39697424
PMCPMC11650614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.